All In Biotech

NDA 021445 · Organon

Zetia

Ezetimibe · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Feb 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2002

Oct 25, 2002

Approved uses

6

Original approval plus efficacy supplements

Registered trials

422

153 Phase 3, 37 recruiting

FAERS reports

76,879

50,222 serious, 4,407 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZETIA · EZETIMIBE 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ezetimibe" as an intervention, any sponsor and status, largest first.

All 422 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue5,145
  • myalgia4,604
  • nausea4,572
  • diarrhoea4,115
  • drug ineffective3,829
  • dizziness3,694
  • dyspnoea3,566
  • headache3,507
  • arthralgia3,164
  • asthenia3,019
  • pain2,984
  • fall2,509

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,321
20052,248
20061,524
20071,599
20081,797
20091,831
20102,315
20112,115
20122,269
20131,897
20142,064
20153,133
20163,057
20172,994
20183,683
20194,009
20204,037
20213,990
20224,656
20235,346
20246,185
20257,349
20266,459

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zetia (Ezetimibe)

2024 spending

$5.8M

Beneficiaries

1,813

7,124 claims

Per beneficiary

$3,219

$12.44 per unit

View as table
YearSpending
2020$0
2021$2,290,305
2022$6,962,985
2023$6,702,955
2024$5,835,522

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 975 on PubMed

Sponsor: Organon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.